Interventional Nanotheranostics for Translational Nano-Immunotherapy

Dear Colleagues,

Cancer immunotherapy activating the immune system to kill cancer cells has emerged as a robust strategy to treat primary, metastatic, and recurred cancers. Recent rapid progress in understanding anticancer immunity and various immune-modulating molecules has initiated a broad range of preclinical research and clinical trials of cancer immunotherapy. Cancer immunotherapies are becoming one of the standard therapies for cancer patients. However, the overall response rate is still moderate due to the therapeutic resistance. Multifunctional nanoparticles have shown a substantial opportunity to enhance the therapeutic efficacy of various types of cancer immunotherapies. Interventional oncology (IO) allowing simultaneous diagnosis, immunogenic local therapeutic delivery, and real-time monitoring of treatment efficacy also have advanced to demonstrate the effective conversion of the tumor microenvironment for the effective anticancer immune response and allows effective local immunotherapy. New approaches combining nanotheranositcs, interventional oncology, and immunotherapy are required to enhance immunotherapeutic efficacy.

The intent of this Special Issue is to collect cutting-edge research on multifunctional materials and mediated, image-guided immunotherapy technology to provide new perspectives into cancer immunotherapy, interventional oncology, and nanotheranostics. 

This Special Issue is intended to cover the following topics but is not limited to them:

• Multifunctional micro/nanocarriers for cancer immunotherapy;
• New interventional oncology and immuno-oncology approaches using multifunctional carrier materials;
• Smart nanomaterials for immune checkpoint inhibitor cancer immunotherapy;
• Tumor microenvironment modulating nanomaterials for combinational cancer immunotherapy;
• Interventional oncology ablation and combinational cancer immunotherapy;
• Characterization of the tumor microenvironment and immune response after interventional oncology local combinational immunotherapies;
• Nanotheranostics for cancer immunotherapy.

Any works concerning nano-immunotherapy, combinational interventional oncology-based local therapy, immunotherapy, and image-guided immunotherapy for the treatment of various types of cancers, as well the characterization of the tumor microenvironment and immune= response of new image-guided cancer immunotherapy approaches will be within the scope of this Special Issue. All submitted papers must present novel results or the advancement of previously published data, and the matter should be dealt with scientific rigor.

Prof. Dr. Dong-Hyun Kim
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Nanotheranostics is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.